If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
ZypAdhera Summary of Product Characteristics (SmPC)
ZypAdhera® (olanzapine pamoate): Switch Between 2-weeks and 4-weeks Interval
Doses of 150 mg/2 weeks or 300 mg/4 weeks are recommended. Doses of 210 mg/2 weeks or 405 mg/4 weeks are recommended. There is no 4-week dose equivalent for doses of 300 mg/2 weeks.
should be treated initially with oral olanzapine before administering
olanzapine pamoate, to establish tolerability and response.1
order to identify the first olanzapine pamoate dose for all patients,
the scheme in Table 1
should be considered.1
1. Recommended dose scheme between oral olanzapine and olanzapine
oral olanzapine dose
starting dose of olanzapine pamoate
dose after 2 month of olanzapine pamoate treatment
or 405 mg/4 weeks
or 300 mg/4 weeks
or 405 mg/4 weeks
treatment, dose may subsequently be adjusted on the basis of
individual clinical status. After clinical reassessment, dose may be
adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to
405 mg every 4 weeks (Table 1).1
full information on dosing please refer to the summary of product
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
Date of Last Review:May 01, 2019
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com